

Performance (consolidated)

(¥ million)

	2013	2014	2015	2016	2017	2018	2019 (estimated)
Net Sales	76,517	79,991	84,209	98,781	101,448	114,716	116,000
Operating profit	8,038	8,562	8,549	15,280	17,079	20,644	21,000
Ordinary Profit	8,598	8,928	8,952	16,244	17,451	21,540	22,000
Profit attributable to owners of the parent	5,750	5,882	6,340	11,749	12,953	16,302	16,500

(¥ million)

Brand name	Active Ingredient	Indications	Launch Date	Sales 2017	Sales 2018	Sales 2019		
						Apr.-Jun.	Apr.-Sep. (estimated)	Annual (estimated)
Vidaza	azacitidine	myelodysplastic syndrome	Mar-11	15,643	14,453	3,912	7,500	14,500
Zalutia	tadalafil	urinary disorder caused by benign prostatic hyperplasia	Apr-14	10,449	12,118	3,401	6,500	13,000
Tramal, Onetram	tramadol hydrochloride	cancer pain, chronic pain	Sep-10	6,622	7,196	1,940	3,800	7,500
Upravi	selexipag	pulmonary arterial hypertension	Nov-16	2,690	4,825	1,566	3,400	7,300
Adcirca	tadalafil	pulmonary arterial hypertension	Dec-09	4,617	5,173	1,452	2,800	5,400
Cialis	tadalafil	erectile dysfunction	Jul-09	3,825	4,592	1,073	2,000	3,700
Gazyva	obinutuzumab	CD20-positive follicular lymphoma	Aug-18	-	1,417	1,014	1,600	3,500
Lunabell	norethisterone and ethinylestradiol	dysmenorrhea	Jul-08	5,374	4,658	598	1,100	2,000
Azunol Gargle	sodium gualenate	pharyngitis, tonsillitis, stomatitis, etc.	Aug-02	2,363	2,169	539	900	2,050
Eviprostat	herbal extracts	benign prostatic hyperplasia	Apr-67	2,761	2,137	499	1,000	1,800
Erizas	dexamethasone cipeclate	allergic rhinitis	Dec-09	2,916	2,987	396	650	2,700
Profit in co-promotion				3,962	5,057	1,464	2,600	5,800
Revenues from the licensing of industrial				10,378	16,621	3,822	7,800	16,800
Pharmaceuticals				87,416	100,223	25,652	49,600	101,100
Functional Food				14,031	14,492	3,739	7,400	14,900
Net Sales				101,448	114,716	29,391	57,000	116,000